



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: July 6, 2007

To: Primary Clinical Research Associates

From: Janis Wobschall
Protocol Development Coordinator

Re: N0572: A Phase I/II trial of Sorafenib and CCI-779 in Recurrent Glioblastoma

In addition to the changes noted in Addendum 3, please find a revised Pathology Reporting Form. A line has been added at the bottom for research/banking information. Please replace your current version of the forms packet with this revised version.

If you have any questions, please feel free to contact me at 507/284-4852.

JW/dg
Enclosure